Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial. (IPaC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01865396|
Recruitment Status : Completed
First Posted : May 30, 2013
Last Update Posted : December 1, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The World Health Organization (WHO) defines palliative care as an approach to improve the quality of life of patients and their families facing life-threatening illness, through prevention and relief of pain and of physical, psychosocial and spiritual problems. The WHO stresses that palliative care is applicable early in the course of the illness together with other therapies that are intended to cure or prolong life, such as chemotherapy or radiation therapy. For the benefit of the patient, palliative care is however often given (too) late in the course of the disease of incurably ill patients.
The aim of our study is to measure the effect of interventional palliative care on quality of life, mood and end-of-life care of patients with advanced cancer and their families. These patients have a limited life expectancy and a high symptom burden, this leads us to suggest that these patients may be benefited with palliative care soon after diagnosis of metastatic disease (interventional palliative care).
The research design of this study is a randomized controlled trial with, on the one hand, an intervention group in which patients and their families receive interventional palliative care in combination with standard cancer care and on the other hand a control group in which patients and their families receive only standard oncologic care. Participants in the intervention group will meet the palliative support team shortly after diagnosis. Afterwards, the palliative support will meet them at least once a month. This intervention focuses on topics such illness understanding, symptom management, decision making and coping with the disease. Participants in the control group will only meet with the palliative support team at the patient's own request or after referral by the oncologist or the nursing staff.
|Condition or disease||Intervention/treatment||Phase|
|Life-limiting Cancer With Prognosis of Approximately 1 Year||Behavioral: Interventional palliative care Behavioral: Standard oncologic care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||268 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||April 2017|
|Actual Study Completion Date :||April 2017|
Experimental: early palliative care
Interventional palliative care, after diagnosis and once a month.
Behavioral: Interventional palliative care
Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
Active Comparator: Standard care
Patients will receive the standard oncologic care.
Behavioral: Standard oncologic care
Patients will receive standard oncologic care.
- Quality of life of the patient and his family caregiver at baseline. [ Time Frame: at baseline ]This will be measured with validated questionnaires(EORTC-QLQ C30, McGill QoL, SF-36).
- Quality of life of the patient and his family caregiver at 12 weeks. [ Time Frame: at 12 weeks ]This will be measured with validated questionnaires (EORTC-QLQ C30, McGill QoL, SF-36).
- Quality of life of the patient and his family caregiver, 6-weekly after 12 weeks. [ Time Frame: 6-weekly after 12 weeks ]This will be measured with validated questionnaires (EORTC-QLQ C30, McGill QoL, SF-36).
- Influence of palliative care on mood and illness-understanding of patients and family caregivers at baseline. [ Time Frame: at baseline. ]This will be measured with validated questionnaires (HADS, PHQ-9, illness understanding).
- Influence of palliative care on mood and illness-understanding of patients and family caregivers at 12 weeks. [ Time Frame: at 12 weeks ]This will be measured with validated questionnaires (HADS, PHQ-9, illness understanding).
- Influence of palliative care on mood and illness-understanding of patients and family caregivers 6-weekly, after 12 weeks. [ Time Frame: 6-weekly, after 12 weeks. ]This will be measured with validated questionnaires (HADS, PHQ-9, illness understanding).
- Influence of palliative care on the decision of physicians with regards to end-of-life-care. [ Time Frame: after death of patient ]This will be measured with the questionnaire for decisions wuth regards to end-of-life decision making for physicians.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients with life-limiting cancer (prognosis of approximately 1 year) are eligible if:
Patients are within 12 weeks of referral from an other hospital after receiving first line treatment or within 8 to 12 weeks of a new diagnosis (histological and cytological confirmed):
- Metastatic and advanced pancreatic, stomach, oesophageal and biliary tract adenocarcinoma;
- Metastatic or advanced NSCLC (stage IIIB or IV) or metastatic SCLC,
- Malignant pleural mesothelioma
- Metastatic or advanced head and neck cancer (stage III or IV)
Patients are within 12 weeks of progression after receiving treatment and have an prognosis of approximately 1 year:
- Metastatic and locally advanced colorectal cancer, with progression after second line treatment
- Metastatic or advanced prostate carcinoma, after second line treatment
- Advanced breast cancer with visceral and/or brain metastasis, with progression on second or third line treatment
- Metastatic melanoma,
- Metastatic or advanced kidney cancer,
- Metastatic or advanced bladder cancer after first line treatment,
An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 and ability to read and respond to questions in Dutch.
- Patients under 18 years old
- Patients with impaired cognition
- Patients who met the palliative support team more then once or had a consultation within 6 months of inclusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01865396
|Ghent University Hospital|
|Ghent, Belgium, 9000|
|Study Director:||Simon Vanbelle, MD, PhD||University Hospital, Ghent|
|Study Chair:||Luc Deliens, PhD, MD||Vrije Universiteit Brussel and Ghent University|
|Responsible Party:||University Ghent|
|Other Study ID Numbers:||
|First Posted:||May 30, 2013 Key Record Dates|
|Last Update Posted:||December 1, 2021|
|Last Verified:||November 2021|